Maddie Meyer/Getty Images News
- Moderna’s (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data when it could be released by the end of the month, according to Leerink.
- “MRNA expects to accrue the 81 cases necessary
